Oragenics, Inc.
ASE: OGENLive Quote
About Oragenics, Inc.
Healthcare
Biotechnology
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida.
📊 Fundamental Analysis
Oragenics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -243.9%, which indicates that capital utilization is currently under pressure.
At a current price of $0.60, OGEN currently trades near the bottom of its 52-week range (1%), indicating potential value or weakness (Range: $0.50 - $9.60).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$2.71M
Trailing P/E
--
Forward P/E
-0.06
Beta (5Y)
1.21
52W High
$9.60
52W Low
$0.50
Avg Volume
547K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App